


Anti-IRAK4 Recombinant Antibody Products

Anti-IRAK4 Products
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: WB, ELISA, FC, IHC
-
- Species Reactivity: Human
- Type: ADCC enhanced antibody
-
- Species Reactivity: Human
- Application: ELISA, IHC-P, WB
- Mouse Anti-IRAK4 Antibody, mRNA (TAB-451CL-mRNA)
-
- Species Reactivity: Human
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: ELISA, WB, FC
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: WB, IHC-Fr, IHC-P, ICC, IF
- Mouse Anti-NHP IRAK4 Recombinant Antibody (clone 2H9) (VS-1024-XY284)
-
- Species Reactivity: Human, Mouse, Non-human primate
- Type: Mouse IgG1
- Application: WB, IHC, FC, ELISA
- Mouse Anti-IRAK4 Recombinant Antibody; scFv Fragment (TAB-0587CL-S(P)) (TAB-0587CL-S(P))
-
- Species Reactivity: Human
- Type: Mouse scFv
- Application: ELISA
- Mouse Anti-IRAK4 Recombinant Antibody; Fab Fragment (TAB-0587CL-F(E)) (TAB-0587CL-F(E))
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: ELISA
- Anti-Human IRAK4 Recombinant Antibody (TAB-451CL)
-
- Species Reactivity: Human
- Type: Antibody
- Mouse Anti-IRAK4 Monoclonal Antibody (VS7-0425-WR149) (VS7-0425-WR149)
-
- Species Reactivity: Human, Mouse, Monkey
- Type: Mouse IgG
- Application: WB, IHC-P, IF, FC, ELISA
- Anti-IRAK4 Immunohistochemistry Kit (VS-0525-XY3582)
-
- Species Reactivity: Human
- Target: IRAK4
- Application: IHC
- Anti-Human IRAK4 Immunohistochemistry Kit (VS-0525-XY3583)
-
- Species Reactivity: Human, Canine
- Target: IRAK4
- Application: IHC
-
- Derivation: Phage display library screening
- Species Reactivity: Human
- Type: IgG
- Application: ICC, WB
-
- Species Reactivity: Human
- Type: IgG
- Application: WB, IF, ICC, IHC-P, FC, ChIP
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is a trusted provider of high - quality anti - IRAK4 antibodies, essential for driving breakthroughs in biomedical research. Our commitment to precision and consistency is reflected in our stringent quality control protocols, ensuring each antibody delivers reliable and reproducible performance. We strive to equip researchers with dependable tools that fuel scientific progress.
IRAK4: A Key Signaling Kinase in Innate Immune Responses
IRAK4, or Interleukin-1 receptor-associated kinase 4, is a pivotal element in the TLR and IL-1R signaling cascades, playing a crucial part in triggering innate immune reactions. By facilitating the activation of downstream signals, it promotes the synthesis of inflammatory cytokines. Deviations in IRAK4 function have been linked to autoimmune diseases, persistent inflammation, and specific malignancies. Given its central position in immune modulation, IRAK4 represents an attractive target for therapeutic strategies, particularly in conditions such as rheumatoid arthritis, lupus, and B-cell cancers. Consequently, there is an increasing focus on creating IRAK4-targeted inhibitors and antibodies for both research endeavors and clinical treatments.
Alternative Names
IPD1; IMD67; REN64; IRAK-4; NY-REN-64
Background
This gene encodes a kinase that activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. The protein is essential for most innate immune responses. Mutations in this gene result in IRAK4 deficiency and recurrent invasive pneumococcal disease. Multiple transcript variants encoding different isoforms have been found for this gene.
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets
Intracellular
Low cell type specificity
Low immune cell specificity
Cell line enhanced (U-937)
Associates with MYD88 and IRAK2 to form a ternary complex called the Myddosome (PubMed:16951688, PubMed:24316379). Once phosphorylated, IRAK4 dissociates from the receptor complex and then associates with the TNF receptor-associated factor 6 (TRAF6), IRAK1, and PELI1; this intermediate complex is required for subsequent NF-kappa-B activation (PubMed:11960013, PubMed:12496252, PubMed:16951688). Direct binding of SMAD6 to PELI1 prevents complex formation and hence negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-mediated gene expression (PubMed:16951688). Interacts with IL1RL1 (PubMed:16286016). Interacts (when phosphorylated) with IRAK1 (PubMed:33238146). May interact (when phosphorylated) with IRAK3 (PubMed:33238146).
Kinase, Serine/threonine-protein kinase, Transferase
Anti-IRAK4 rAb Products
We specialize in providing high-quality anti-IRAK4 recombinant antibodies to support research in drug development. Committed to scientific progress, we offer reliable and effective products to enhance target-related studies. Our focus is on delivering dependable solutions that empower researchers in advancing their discoveries.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOB-2079z | Mouse Anti-IRAK4 Recombinant Antibody (clone 27A3) | Human | Mouse | WB; ELISA; FC; IHC |
TAB-451CL | Anti-Human IRAK4 Recombinant Antibody | Human | Mouse | ELISA |
VS3-FY761 | Recombinant Rabbit Anti-IRAK4 Antibody (clone R01-1B2) | Human | Rabbit | WB; IHC; ICC; IF |
MOB-0992CT | Recombinant Mouse anti-Human IRAK4 Monoclonal antibody (A8A8) | Human | Mouse | ELISA; IHC; WB |
Creative Quality Control
We are committed to delivering antibody products of exceptional quality, carefully developed using cutting-edge technologies and stringent quality control standards. Through providing these premium antibodies, we aim to support scientific research and aid in the development of more effective IRAK4-targeted therapies.
Fig.1 WB analysis of anti-IRAK4 antibody
(Cat# VS3-FY761, Creative Biolabs).
Fig.2 IHC-P analysis of anti-IRAK4 antibody
(Cat# VS3-FY761, Creative Biolabs).
Customer Reviews

Recombinant Rabbit Anti-IRAK4 Antibody (clone R01-1B2) (Cat#: VS3-FY761)

Mouse Anti-IRAK4 Recombinant Antibody (clone 27A3) (Cat#: MOB-2079z)
rAb Production
With years of specialized experience in expression vector design, transfected cell line screening, and antibody purification, we offer a full range of services from gene synthesis to antibody production. We are committed to providing dependable, high-quality products designed to support the unique requirements of biomedical researchers. By emphasizing consistency and streamlined processes, we help scientists advance their work efficiently and effectively. Our focus on quality and reliability contributes to progress in both research and therapeutic innovation.
Featured Anti-IRAK4 Recombinant Antibody Production Platforms
Fig.3 Milligram-scale recombinant antibody production.
Fig.4 Gram-scale recombinant antibody production.
rAb Modalities
Our team focuses on offering a wide range of recombinant antibody formats to support various scientific applications, such as basic research and drug discovery. Our antibodies are meticulously designed to address the unique requirements of researchers, ensuring top-notch quality and dependability. By providing flexible solutions, we strive to foster scientific progress and aid in advancing biomedical research, empowering researchers to make impactful discoveries.
Fig.5 Full Length Anti-IRAK4 Recombinant Antibody Production and Modalities.
Drug Information Targeting IRAK4
Table 1. Therapeutic approaches targeting IRAK4 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase II | Kymera Therapeutics | Small Molecules | Atopic dermatitis; Hidradenitis suppurativa | It is an orally available IRAK4 degradation inducer, is in phase II clinical development for the treatment of hidradenitis suppurativa and atopic dermatitis. |
Phase II | Gilead | Small Molecules | Cutaneous lupus erythematosus; Inflammatory bowel disease | It is an oral, small-molecule inhibitor of the IRAK-4 kinase in phase II clinical development as a treatment for cutaneous lupus erythematosus. |
Phase II | Bayer | Small Molecules | Atopic dermatitis; Endometriosis | It is an oral, small-molecule IRAK-4 inhibitor in early clinical development for the treatment of immune-mediated inflammatory disorders. |
Phase I/II | Aurigene | Small Molecules | Acute myeloid leukemia; Cancer | It is an orally available small molecule inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK4). |
Phase I | AstraZeneca | Others | Inflammatory disorders | It is an orally available interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitor in early clinical development for the treatment of inflammatory disorders. |
Phase I | Rigel | Others | Myelodysplasia | This is an oral dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being developed in phase I studies for the treatment of patients with lower-risk myelodysplastic syndromes (MDS) who are refractory or resistant to prior therapies. |
Phase I | Eilean Therapeutics | Others | Acute myeloid leukemia | It is an oral selective pan-FLT3/ IRAK4 inhibitor in phase I development for the treatment of FLT3 mutated acute myeloid leukemia (AML). |
If you're interested in learning more about our anti-IRAK4 recombinant antibodies or have any inquiries, don't hesitate to reach out us. Our skilled team is dedicated to providing full support, offering expert advice and customized solutions to suit your research needs. We aim to provide a smooth experience, helping you achieve reliable and significant outcomes in your scientific endeavors. Your success is our priority, and we're here to assist you every step of the way.